Jim has been the founder, inventor, investor, and owner operator in many med-tech / biotech ventures. Having started and operated over 8 different companies since 1990, Jim began working on the Matrix technology, the backbone for InSitu’s sustained release drug, AnestaGel, in 2007 and co-founded InSitu Biologics in 2014. Xerox trained out of college, Jim specializes in the total operation for small companies.
For more information:
https://www.linkedin.com/in/james-segermark-8758a0161/